Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

22 trials match this view; 28 reported facilities; 28 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 931 across 22 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20171
20181
20202
20212
20237
20244
20253
20262

Current indexed registry status

Recruiting6
Completed6
Active, not recruiting5
Withdrawn3
Terminated1
Unknown status1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

22 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Effects of Psilocybin in Major Depressive Disorder

NCT03181529

Major Depressive Disorder
Johns Hopkins University

PHASE2

Completed

Registry updated 2021-12-15

27

ACTUAL

2017-08-10
2020-12-02
2020-12-02
Evidence-guide report · Davis et al. · 2021
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174

Major Depressive Disorder
Yale University

PHASE1

Active, not recruiting

Registry updated 2026-11-05

18

ESTIMATED

2018-02-27
2021-07-08
2026-12
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563

Major Depressive Disorder
Maryland Oncology Hematology, PA

PHASE2

Unknown status

Registry updated 2021-10-15

30

ACTUAL

2020-09-01
2022-10
2023-10
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control

NCT04353921

Major Depressive Disorder
Usona Institute

Phase not reported

Terminated

Registry updated 2026-05-04

26

ACTUAL

2020-06-30
2022-10-18
2022-10-18
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

NCT05594667

Depression · Major Depressive Disorder · Mild Depression · Moderate Depression · Depressive Disorder
Cybin Therapeutics Inc.

PHASE2

Withdrawn

Registry updated 2023-07-06

0

ACTUAL

2023-01-01
2023-03-14
2023-03-14
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964

Major Depressive Disorder · Depression
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Completed

Registry updated 2024-04-19

35

ACTUAL

2021-01-01
2023-04-19
2024-04-18
Evidence-guide report · Yngwe et al. · Stockholm trial · 2026
Microdosing Psychedelics to Improve Mood

NCT05259943

Major Depressive Disorder
Rotem Petranker

PHASE2

Completed

Registry updated 2026-10-20

39

ACTUAL

2023-07-15
2024-12-21
2025-02-01
Psilocybin for the Treatment of Major Depressive Disorder

NCT05675800

Major Depressive Disorder
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2024-07-25

0

ACTUAL

2024-01-01
2025-01-01
2025-03-31
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression

NCT05601648

Major Depressive Disorder · Anhedonia
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2023-01-30

0

ACTUAL

2023-07-01
2025-01-01
2025-07-01
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial

NCT06746441

Major Depressive Disorder
Khyber Medical University Peshawar

PHASE2

Completed

Registry updated 2025-09-02

60

ACTUAL

2024-12-01
2025-06-01
2025-07-30
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546

Major Depressive Disorder
COMPASS Pathways

PHASE2

Active, not recruiting

Registry updated 2025-08-19

102

ACTUAL

2023-01-30
2025-09
2025-09
Psilocybin-assisted Cognitive Behavioral Therapy for Depression

NCT05227612

Major Depressive Disorder
University of California, Los Angeles

PHASE1

Completed

Registry updated 2026-05-19

16

ACTUAL

2023-06-27
2025-09-12
2025-09-12
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

NCT05399498

Borderline Personality Disorder · Major Depressive Disorder
University of Chicago

PHASE2

Completed

Registry updated 2026-10-29

10

ACTUAL

2023-11-01
2025-12-01
2025-12-01
Posted registry results
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759

Major Depressive Disorder · Alcohol Use Disorder
Johns Hopkins University

PHASE2

Active, not recruiting

Registry updated 2026-03-13

90

ESTIMATED

2021-04-14
2026-03-02
2027-03-30
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426

Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-07-09

92

ESTIMATED

2024-02-05
2026-07-28
2026-12-28
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer

NCT05947383

Cancer · Major Depressive Disorder
Sunstone Medical

PHASE2

Active, not recruiting

Registry updated 2026-05-06

56

ESTIMATED

2023-10-23
2027-04-30
2027-11-01
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

NCT07703722

Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Khyber Medical University Peshawar

PHASE3

Recruiting

Registry updated 2026-07-14

60

ESTIMATED

2026-04-01
2027-10-22
2027-11-22
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

NCT06072898

Depressive Disorder · Major Depressive Disorder
Sunnybrook Health Sciences Centre

PHASE2

Recruiting

Registry updated 2026-03-30

50

ESTIMATED

2025-05-28
2028-05
2029-05
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839

Major Depressive Disorder
Sharmin Ghaznavi

PHASE3

Recruiting

Registry updated 2026-08-13

20

ESTIMATED

2024-09-10
2028-06-30
2028-06-30
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-10-20

40

ESTIMATED

2026-11-01
2028-11
2028-11
Registry-linked result · PMID 27210031
Registry-linked result · PMID 33146667
Registry-linked result · PMID 36322843
Registry-linked result · PMID 31060042
Registry-linked result · PMID 31636488
Registry-linked result · PMID 37651119
Registry-linked result · PMID 27909164
Registry-linked result · PMID 20717121
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

NCT06592833

Major Depressive Disorder
Icahn School of Medicine at Mount Sinai

PHASE2

Recruiting

Registry updated 2026-11-06

60

ESTIMATED

2025-02-25
2029-03
2029-04
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31

Reported research facilities

Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada · Coordinates available
Centre for Neurology Studies x UpstreamAbbotsford British Columbia, British Columbia, Canada · Coordinates available
Psych ResearchToronto, Ontario, Canada · Coordinates available
Sunnybrook Health Sciences CentreToronto, Ontario, Canada · Coordinates available
Toronto Western HospitalToronto, Ontario, Canada · Coordinates available
Hayatabad Medical Complex PeshawarPeshawar, KPK, Pakistan · Coordinates available
Institute of Health Science, Khyber Medical UniversityIslamabad, Capital, Pakistan · Coordinates available
Khyber Medical UniversityPeshawar, KPK, Pakistan · Coordinates available
Lady Reading Hospital, PakistanPeshawar, Khyber Pakhtunkhwa, Pakistan · Coordinates available
Northern Stockholm Spychiatry ClinicStockholm, Sweden · Coordinates available
Aims TrialPlano, Texas, United States · Coordinates available
Athinoula A. Martinos Center for Biomedical ImagingCharlestown, Massachusetts, United States · Coordinates available
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore, Maryland, United States · Coordinates available
Clinical Neuroscience Solutions IncJacksonville, Florida, United States · Coordinates available
Elixia MA, LLCSpringfield, Massachusetts, United States · Coordinates available
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States · Coordinates available
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States · Coordinates available
Innovative Clinical Research, Inc. (formerly Segal Trials)Lauderhill, Florida, United States · Coordinates available
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States · Coordinates available
Kadima Neuropsychiatry InstituteLa Jolla, California, United States · Coordinates available
Maryland Oncology Hematology PARockville, Maryland, United States · Coordinates available
Sunstone Medical, PCRockville, Maryland, United States · Coordinates available
Sunstone TherapiesRockville, Maryland, United States · Coordinates available
The Ohio State University Department of PsychiatryColumbus, Ohio, United States · Coordinates available
UCLA Semel InstituteLos Angeles, California, United States · Coordinates available
University of ChicagoChicago, Illinois, United States · Coordinates available
VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States · Coordinates available
Washington University School of MedicineSt Louis, Missouri, United States · Coordinates available

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.